A Decade Of Novel CDER Approvals, By The Numbers
Executive Summary
Pink Sheet infographic illustrates new drug approval trends and highlights from the past decade at the US FDA.
You may also be interested in...
Long Hot Summer For Novel Drug Reviews Forecast At US FDA
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Sharfstein: US FDA Incentives Not Broke, But Fix Them
The former US FDA principal deputy commissioner argues that accelerated approval, fast track and breakthrough designation standards may need updating, along with orphan and pediatric exclusivity requirements, to enhance the programs' efficacy.
Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker